[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100257893":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":10,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1",null,"Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).",[13],"Drug: No Intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","No Intervention","This is an observational study and participants did not receive any intervention in this study.",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Janssen Research & Development, LLC Clinical Trials","STUDY_DIRECTOR",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100257893","study-on-incidence-of-diabetic-ketoacidosis-among-participants-with-type-2-diabetes-mellitus-treated-with-sodium-glucose-co-transporter-2-sglt2-inhibitors-or-other-antihyperglycemic-agents-100257893",false,"NCT02636192","Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents","Incidence of Diabetic Ketoacidosis Among Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors or Other Antihyperglycemic Agents- A Retrospective, Observational, New-User Cohort Study Using 4 Administrative Claims Databases in the US","Inclusion Criteria:\n\n* At least 1 antihyperglycemic agents (AHA) prescription (Rx) during the study period, between 4\u002F1\u002F2013 and 9\u002F30\u002F2014.\n* Diagnosed of type 2 diabetes mellitus\n* Enrollment history of at least 12 months\n* Having prescription drug coverage\n* Having no prescription of the index drug during the 6 months prior\n\nExclusion Criteria:\n\n\\- Participants who receive diagnosis of type1 diabetes mellitus (T1DM) and\u002For secondary diabetes mellitus (SDM) any time after index date.","ALL","18 Years",{"count":40,"type":41},200000,"ACTUAL","OBSERVATIONAL","The purpose of this study is to compare the incidence of diabetic ketoacidosis (DKA) among participants diagnosed with type 2 diabetes mellitus (T2DM) and pair-matched on exposure propensity scores for new use of any sodium-glucose co-transporter 2 inhibitors (SGLT2i) versus new use of various other antihyperglycemic agents (AHAs), combined as one group.",[45],"Diabetes Mellitus, Type 2",[47,45],"Sodium-glucose co-transporter 2 inhibitors","COMPLETED","2017-04-12",{"date":51,"type":41},"2017-04-13",{"date":53,"type":41},"2015-07-31",{"date":55,"type":41},"2017-04-07",{"name":5,"class":6}]